Navigation Links
Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
Date:3/10/2008

administered once every three weeks. The most common adverse events reported thus far include nausea, fatigue, vomiting and alopecia. There was a low rate of febrile neutropenia or other Grade 3/4 adverse events, and manageable Grade 1/2 nausea or vomiting.

Based on the indications of clinical activity and the acceptable tolerability profile demonstrated to date among this patient population, the dose of SNS-595 in this trial has been increased to 60 mg/m2 over twenty-eight days. Patient accrual at this dose level is ongoing.

"We are pleased by the strong signal of activity emerging from our Phase 2 clinical trial of SNS-595 at the 48mg/m2 dose level. Based on the drug's observed safety profile and recommendations from advisors, we are exploring a higher dose of SNS-595 in this trial. Enrollment has begun at 60 mg/m2 and we expect to enroll approximately 30 patients at this dose by the third quarter of this year," said Daniel C. Adelman, M.D., Senior Vice President, Development and Chief Medical Officer of Sunesis. "Enthusiasm for SNS-595 among our clinical investigators is growing and enrollment in this trial has been accelerating. We expect to present further data from this Phase 2 clinical trial this year."

The interim clinical results are being presented in a poster, "A Phase 2 Trial of SNS-595 in Women with Platinum-Refractory Epithelial Ovarian Cancer" (Abstract # 290), at the 39th Annual Meeting on Women's Cancer hosted by the Society of Gynecologic Oncologists (SGO) in Tampa, Fla. through March 12, 2008.

About SNS-595

SNS-595 is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. SNS-595 is a specific DNA intercalator and topoisomerase II poison, causing replication-dependent site-selective double strand DNA damage, irreversible G2 arrest and rapid apoptosis. In non-clinical evaluations, SNS-595 demonstrates broad and potent a
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
4. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
5. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
6. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
7. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
8. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
9. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
10. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
11. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... June 30, 2015 Today, UBM China, a ... agreement with Chengdu Tianyi Exhibition Co., Ltd. to jointly ... is to be held concurrently with CWMEE 2016. ... healthcare exhibition family, following MEDTEC China and DENTECH China, ... in west China. It,s also another concrete cooperative project ...
(Date:6/30/2015)... und KOPENHAGEN, Dänemark, 30. Juni 2015 /PRNewswire/ ... Weltmarktführer der klinischen und kommerziellen Produktion von ... heute bekannt, dass das Unternehmen im Rahmen ... der nordamerikanischen Produktionsanlage in Bothell, ... Einweg-Anlage Bioreactor 6Pack™ komplettiert hat. Die Konfiguration ...
(Date:6/30/2015)... 2015  EnteroMedics Inc. (NASDAQ: ETRM ), a ... to treat obesity, metabolic diseases, and other gastrointestinal disorders, ... of 40,229,886 units. Each unit consists of one share ... to purchase one share of common stock, and 0.50 ... of common stock, at a purchase price of $0.87 ...
Breaking Medicine Technology:UBM Joins Chengdu Tianyi to Hold CWMEE 2016 2UBM Joins Chengdu Tianyi to Hold CWMEE 2016 3CMC Biologics baut GMP-Produktionskapazität in den USA aus 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 3EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 3
... Inc. (Nasdaq: OPTR ) today announced it expects ... after the NASDAQ Global Market closes on Thursday, March 10, ... that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific ... fourth quarter and full year 2010, as well as provide ...
... CRANBURY, N.J., March 3, 2011 Palatin Technologies, Inc. (NYSE ... Food and Drug Administration (FDA) has cleared Palatin,s request to ... New Drug (IND) application using a subcutaneously administered formulation of ... acute exacerbations of asthma. "We are excited ...
Cached Medicine Technology:Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results 2FDA Clears Palatin Technologies' IND Filing to Commence Clinical Studies for Asthma 2
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... Ticket Down is a reputable source of ... native of Detroit, MI, Kid Rock, is hitting the road again this summer in what ... and hip hop superstar kicked off his summer tour this year at the XFINITY Theatre ...
(Date:6/30/2015)... ... June 30, 2015 , ... The ... launched a ‘responsive design’ website to inform potential sinus surgery patients about ear, ... The website includes information about a wide variety of ENT issues including hearing ...
(Date:6/30/2015)... ... June 30, 2015 , ... ADVOCATE, the premier provider of ... Mann, CPC, RCC, ROCC, Coding Documentation and Education Manager, was honored at the ... for her contribution to the RBMA Coding Subcommittee. , Ms. Mann served ...
(Date:6/30/2015)... ... June 30, 2015 , ... Today, Grand Terrace Health Care ... Care Center.” Each year, Medicare ranks care centers around the country in an ... their needs. Grand Terrace prides itself on quality in each of Medicare’s evaluation ...
(Date:6/30/2015)... ... 30, 2015 , ... According to a June 15th report from ... how sensory stimuli can be used to “decrease children’s anxiety and negative responses during ... autism, will compare patient experience in a “typical dental environment” with one that provides ...
Breaking Medicine News(10 mins):Health News:Cheap Kid Rock Tickets at the DTE Energy Music Theatre in Clarkston: Ticket Down Has Slashed Prices On All Kid Rock Tickets at DTE in the Detroit Metro Area 2Health News:Clear Lake Medical Center ENT Launches ‘Responsive Design’ Website 2Health News:Clear Lake Medical Center ENT Launches ‘Responsive Design’ Website 3Health News:ADVOCATE’s Debby Mann Honored With Special Recognition Award 2Health News:Grand Terrace Health Care Center Announces Five-Star Rating in YouTube Video 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 3
... , MONDAY, April 23 (HealthDay News) -- Hispanic people ... black people with the disease, according to a new study. ... due to genetic factors or environmental advantages, such as lower ... examined diagnosis and survival data on cancer patients from a ...
... Army Medical Center (BAMC)/San Antonio Military Medical Center (SAMMC) will ... that he hopes will extend the shelf life of and ... Maj. Jean M. Muderhwa is slated to present at 12:25 ... on a microemulsion he developed and that has been found ...
... April 20 (HealthDay News) -- Searching for a favorite song ... distracted driving, researchers say. About 90 percent of new ... makers of aftermarket MP3 controllers make devices claimed to decrease ... according to the new study. The study included 50 ...
... April 2012): Widespread screening of children in poorer countries is ... rheumatic heart disease (RHD) in patients that would likely have ... carried out in Fiji and Uganda presented today at the ... control programmes can help to identify patients before they progress ...
... (HealthDay News) -- The breed of dog a person chooses ... new study suggests. The online survey of 1,000 ... England, found certain personality traits, such as extroversion, agreeableness and ... is to be presented Friday at the British Psychological Society ...
... studies analyzing treatment decisions in late-stage amyotrophic lateral sclerosis ... the duration and quality of life in this progressively ... Medicine at the University of Pennsylvania found that waiting ... in not living long enough to experience the benefits. ...
Cached Medicine News:Health News:Hispanics Seem to Have Better Odds of Lung Cancer Survival 2Health News:Army researcher develops potential vaccine carrier 2Health News:Army researcher develops potential vaccine carrier 3Health News:Long MP3 Playlists Lead to Distracted Drivers 2Health News:Screening programs detect cases of undiagnosed rheumatic heart disease in low-resource countries 2Health News:Could Your Personality Be Reflected in Your Pooch? 2Health News:ALS patients differ on treatment choices in later phases of disease 2
The Maxi-Therm® lite hyper-hypothermia water blankets from Cincinnati Sub-Zero take conductive warming and cooling therapy to a new, softer level. These blankets are soft, lightweight, and remai...
The Neuro-Cool™ System provides pain relief by combining a head wrap with a cold therapy unit for effective migraine treatment....
... The BCI® Oximetry Data Management Program ... for use with the FingerPrint® Sleep ... Smiths Medical PM, Inc. catalog #3389 ... collected during sleep screening, oxygen therapy ...
... The ImmunoWELL Mumps IgG Test ... the qualitative detection of IgG ... are used as an aid ... Immune status may be determined ...
Medicine Products: